Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
about
Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction.A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasiaSilodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.Silodosin in the treatment of benign prostatic hyperplasiaSafety and efficacy of silodosin for the treatment of benign prostatic hyperplasiaNew clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo.Clinical Background of Patients with Sperm in Their Urinary Sediment.Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.Efficacy of Dose Escalation of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms.Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
P2860
Q33739980-C0D5A777-69A2-4FB2-B925-A26F43628447Q34417223-3B27F53A-61AF-4943-8323-5E81CBC0CD0BQ34452517-98891312-F612-4832-BA07-B02C8CF7CFACQ34585420-21904284-0BD0-462E-9509-0F33843281A0Q34625490-59B4F439-0E1B-4AD6-B8D3-768F1ACE25D4Q34630995-8B937947-6F78-40A0-B8A9-4EFFD3E92492Q34635165-B2363C41-B722-4E64-B469-05DCBD45E8ADQ35089850-22DE1D00-05C5-4BAA-A8E0-6477010A580DQ35728166-D974C59E-63D6-4C99-9B9B-E7E85ABAD6ECQ35770400-C78BEC1A-AD54-499D-B9EE-485D3782A9E8Q36116524-E36FC91D-E414-4BA9-963D-8323FD41775CQ36116534-1EEAB346-279F-46C0-919C-F30646BF8BDCQ36371582-2E2C812B-E231-4CB1-8739-3937C0DF1517Q38463030-EB969BC6-04F5-4F90-9829-FCB23CB0FD1AQ38845916-AB8FB110-622A-4353-BCB2-59FEAE8D635FQ45216594-263926E8-414D-4130-881A-22B164FD1AD5Q47434739-483B85A6-5166-4901-BEA8-5885CAE23A2CQ53163585-5CD1D2C2-1F1D-461C-BDD5-F0B6C3B414E6Q53250512-0ACAADEB-D978-4B98-B1AA-8FBBA86E0499
P2860
Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Lower urinary tract symptoms/b ...... morbidity caused by treatment.
@ast
Lower urinary tract symptoms/b ...... morbidity caused by treatment.
@en
type
label
Lower urinary tract symptoms/b ...... morbidity caused by treatment.
@ast
Lower urinary tract symptoms/b ...... morbidity caused by treatment.
@en
prefLabel
Lower urinary tract symptoms/b ...... morbidity caused by treatment.
@ast
Lower urinary tract symptoms/b ...... morbidity caused by treatment.
@en
P1433
P1476
Lower urinary tract symptoms/b ...... morbidity caused by treatment.
@en
P2093
Claude C Schulman
P356
10.1016/S0090-4295(03)00471-0
P407
P433
P577
2003-09-01T00:00:00Z